Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) saw a significant decline in short interest in July. As of July 15th, there was short interest totalling 3,110,000 shares, a decline of 11.4% from the June 30th total of 3,510,000 shares. Based on an average daily volume of 589,600 shares, the days-to-cover ratio is currently […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) – Chardan Capital lifted their FY2023 EPS estimates for 4D Molecular Therapeutics in a research report issued on Tuesday, July 11th. Chardan Capital analyst G. Livshits now anticipates that the company will earn ($2.66) per share for the year, up from their previous estimate of ($3.13). The […]
Chardan Capital began coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report released on Wednesday, Marketbeat.com reports. The firm issued a buy rating and a $30.00 price target on the stock. Several other equities research analysts have also recently issued reports on FDMT. SVB Securities lowered their price objective […]
Chardan Capital started coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report issued to clients and investors on Wednesday, The Fly reports. The brokerage set a “buy” rating on the stock. A number of other analysts have also weighed in on FDMT. HC Wainwright restated a “buy” rating and […]